Cargando…
Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma
SIMPLE SUMMARY: We present two cases of a subtype of retinoblastoma, a rare ocular tumor in children, presenting without the typical mutation in the RB1 gene but showing amplification of the transcription factor MYCN frequently reported in pediatric malignancies. Even though previous reports suggest...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565107/ https://www.ncbi.nlm.nih.gov/pubmed/32971811 http://dx.doi.org/10.3390/cancers12092714 |
_version_ | 1783595864092049408 |
---|---|
author | Zugbi, Santiago Ganiewich, Daiana Bhattacharyya, Arpita Aschero, Rosario Ottaviani, Daniela Sampor, Claudia Cafferata, Eduardo G. Mena, Marcela Sgroi, Mariana Winter, Ursula Lamas, Gabriela Suñol, Mariona Daroqui, Manuel Baialardo, Edgardo Salas, Beatriz Das, Anirban Fandiño, Adriana Francis, Jasmine H. Lubieniecki, Fabiana Lavarino, Cinzia Garippa, Ralph Podhjacer, Osvaldo L. Abramson, David H. Radvanyi, François Chantada, Guillermo Llera, Andrea S. Schaiquevich, Paula |
author_facet | Zugbi, Santiago Ganiewich, Daiana Bhattacharyya, Arpita Aschero, Rosario Ottaviani, Daniela Sampor, Claudia Cafferata, Eduardo G. Mena, Marcela Sgroi, Mariana Winter, Ursula Lamas, Gabriela Suñol, Mariona Daroqui, Manuel Baialardo, Edgardo Salas, Beatriz Das, Anirban Fandiño, Adriana Francis, Jasmine H. Lubieniecki, Fabiana Lavarino, Cinzia Garippa, Ralph Podhjacer, Osvaldo L. Abramson, David H. Radvanyi, François Chantada, Guillermo Llera, Andrea S. Schaiquevich, Paula |
author_sort | Zugbi, Santiago |
collection | PubMed |
description | SIMPLE SUMMARY: We present two cases of a subtype of retinoblastoma, a rare ocular tumor in children, presenting without the typical mutation in the RB1 gene but showing amplification of the transcription factor MYCN frequently reported in pediatric malignancies. Even though previous reports suggested that this tumor sybtype could present metastases, patients with metastatic disease were not reported. Our cases had metastasis to the orbit and lymph nodes and poor sensitivity to standard chemotherapy but no dissemination to the central nervous system, as described for patients with mutations in the RB1. We were able to grow the cells of one of our patients in vitro, perform comprehensive genomic analysis that showed previously not reported mutations and other chromosomal alterations. In an animal model, we could reproduce the clinical dissemination and we identified an innovative active drug combination that could help for the treatment of these children with poor prognosis. ABSTRACT: An uncommon subgroup of unilateral retinoblastomas with highly aggressive histological features, lacking aberrations in RB1 gene with high-level amplification of MYCN (MCYN [Formula: see text] RB1 [Formula: see text]) has only been described as intra-ocular cases treated with initial enucleation. Here, we present a comprehensive clinical, genomic, and pharmacological analysis of two cases of MCYN [Formula: see text] RB1 [Formula: see text] with orbital and cervical lymph node involvement, but no central nervous system spread, rapidly progressing to fatal disease due to chemoresistance. Both patients showed in common MYCN high amplification and chromosome 16q and 17p loss. A somatic mutation in TP53, in homozygosis by LOH, and high chromosomal instability leading to aneuploidy was identified in the primary ocular tumor and sites of dissemination of one patient. High-throughput pharmacological screening was performed in a primary cell line derived from the lymph node dissemination of one case. This cell line showed resistance to broad spectrum chemotherapy consistent with the patient’s poor response but sensitivity to the synergistic effects of panobinostat–bortezomib and carboplatin–panobinostat associations. From these cells we established a cell line derived xenograft model that closely recapitulated the tumor dissemination pattern of the patient and served to evaluate whether triple chemotherapy significantly prolonged survival of the animals. We report novel genomic alterations in two cases of metastatic MCYN [Formula: see text] RB1 [Formula: see text] that may be associated with chemotherapy resistance and in vitro/in vivo models that serve as basis for tailoring therapy in these cases. |
format | Online Article Text |
id | pubmed-7565107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75651072020-10-26 Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma Zugbi, Santiago Ganiewich, Daiana Bhattacharyya, Arpita Aschero, Rosario Ottaviani, Daniela Sampor, Claudia Cafferata, Eduardo G. Mena, Marcela Sgroi, Mariana Winter, Ursula Lamas, Gabriela Suñol, Mariona Daroqui, Manuel Baialardo, Edgardo Salas, Beatriz Das, Anirban Fandiño, Adriana Francis, Jasmine H. Lubieniecki, Fabiana Lavarino, Cinzia Garippa, Ralph Podhjacer, Osvaldo L. Abramson, David H. Radvanyi, François Chantada, Guillermo Llera, Andrea S. Schaiquevich, Paula Cancers (Basel) Article SIMPLE SUMMARY: We present two cases of a subtype of retinoblastoma, a rare ocular tumor in children, presenting without the typical mutation in the RB1 gene but showing amplification of the transcription factor MYCN frequently reported in pediatric malignancies. Even though previous reports suggested that this tumor sybtype could present metastases, patients with metastatic disease were not reported. Our cases had metastasis to the orbit and lymph nodes and poor sensitivity to standard chemotherapy but no dissemination to the central nervous system, as described for patients with mutations in the RB1. We were able to grow the cells of one of our patients in vitro, perform comprehensive genomic analysis that showed previously not reported mutations and other chromosomal alterations. In an animal model, we could reproduce the clinical dissemination and we identified an innovative active drug combination that could help for the treatment of these children with poor prognosis. ABSTRACT: An uncommon subgroup of unilateral retinoblastomas with highly aggressive histological features, lacking aberrations in RB1 gene with high-level amplification of MYCN (MCYN [Formula: see text] RB1 [Formula: see text]) has only been described as intra-ocular cases treated with initial enucleation. Here, we present a comprehensive clinical, genomic, and pharmacological analysis of two cases of MCYN [Formula: see text] RB1 [Formula: see text] with orbital and cervical lymph node involvement, but no central nervous system spread, rapidly progressing to fatal disease due to chemoresistance. Both patients showed in common MYCN high amplification and chromosome 16q and 17p loss. A somatic mutation in TP53, in homozygosis by LOH, and high chromosomal instability leading to aneuploidy was identified in the primary ocular tumor and sites of dissemination of one patient. High-throughput pharmacological screening was performed in a primary cell line derived from the lymph node dissemination of one case. This cell line showed resistance to broad spectrum chemotherapy consistent with the patient’s poor response but sensitivity to the synergistic effects of panobinostat–bortezomib and carboplatin–panobinostat associations. From these cells we established a cell line derived xenograft model that closely recapitulated the tumor dissemination pattern of the patient and served to evaluate whether triple chemotherapy significantly prolonged survival of the animals. We report novel genomic alterations in two cases of metastatic MCYN [Formula: see text] RB1 [Formula: see text] that may be associated with chemotherapy resistance and in vitro/in vivo models that serve as basis for tailoring therapy in these cases. MDPI 2020-09-22 /pmc/articles/PMC7565107/ /pubmed/32971811 http://dx.doi.org/10.3390/cancers12092714 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zugbi, Santiago Ganiewich, Daiana Bhattacharyya, Arpita Aschero, Rosario Ottaviani, Daniela Sampor, Claudia Cafferata, Eduardo G. Mena, Marcela Sgroi, Mariana Winter, Ursula Lamas, Gabriela Suñol, Mariona Daroqui, Manuel Baialardo, Edgardo Salas, Beatriz Das, Anirban Fandiño, Adriana Francis, Jasmine H. Lubieniecki, Fabiana Lavarino, Cinzia Garippa, Ralph Podhjacer, Osvaldo L. Abramson, David H. Radvanyi, François Chantada, Guillermo Llera, Andrea S. Schaiquevich, Paula Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title_full | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title_fullStr | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title_full_unstemmed | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title_short | Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma |
title_sort | clinical, genomic, and pharmacological study of mycn-amplified rb1 wild-type metastatic retinoblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565107/ https://www.ncbi.nlm.nih.gov/pubmed/32971811 http://dx.doi.org/10.3390/cancers12092714 |
work_keys_str_mv | AT zugbisantiago clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT ganiewichdaiana clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT bhattacharyyaarpita clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT ascherorosario clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT ottavianidaniela clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT samporclaudia clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT cafferataeduardog clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT menamarcela clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT sgroimariana clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT winterursula clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT lamasgabriela clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT sunolmariona clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT daroquimanuel clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT baialardoedgardo clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT salasbeatriz clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT dasanirban clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT fandinoadriana clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT francisjasmineh clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT lubienieckifabiana clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT lavarinocinzia clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT garipparalph clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT podhjacerosvaldol clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT abramsondavidh clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT radvanyifrancois clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT chantadaguillermo clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT lleraandreas clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma AT schaiquevichpaula clinicalgenomicandpharmacologicalstudyofmycnamplifiedrb1wildtypemetastaticretinoblastoma |